Table 1.
Allele and genotype frequencies of APOE polymorphisms in control and in PXE subjects.
There were no statistically significant differences between PXE patients and control subjects.
| Genotype/allele | Control (%) (n = 103) | PXE (%) (n = 119) | OR (95% CI) | p valuea |
|---|---|---|---|---|
| Genotype | ||||
| E2E2 | 0 | 0 | ||
| E3E3 | 63.1 | 74.1 | 1.00 (reference) | |
| E4E4 | 1.9 | 0 | 0.1705 (0.008 –3.619) | 0.22 |
| E2E3 | 12.6 | 10.3 | 0.6549 (0.2688–1.595) | 0.37 |
| E3E4 | 21.4 | 13.8 | 0.5676 (0.2667–1.208) | 0.18 |
| E2E4 | 1.0 | 1.7 | 1.703 (0.1507–19.23) | 1.0 |
| Allele | ||||
| e2 | 7 | 6 | 0.7973 (0.2569–2.474) | 0.78 |
| e3 | 80 | 86 | 1.00 (reference) | |
| e4 | 13 | 8 | 0.5725 (0.2254–1.454) | 0.25 |
a
Fisher's test was used; p < 0.05 was considered to be statistically significant.